Topic summary

Follow-up: How compounding permissions changed when supply normalised

Sourcing › Regulatory MHRA personal import research use only

This is a generated summary. It shows the 9 most-liked posts from a topic of 78, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

WendelboeTL2Member16 Jul 2026#28

lyophil_margin, post #10: post #9 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this,… Go to post

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

26 likes in reply to #10 12d

h.bakkerTL2 Moderator18 Jul 2026#36

Coming back to post #34, because the follow-up matters more than the original answer.

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

28 likes 10d

r.friskTL2 Moderator20 Jul 2026#44

post #43 answers the question as asked. The question underneath it is different.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

31 likes 8d

KForsbergTL2Member20 Jul 2026#48

post #47 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

23 likes 7d

s.hartmannTL2 Moderator21 Jul 2026#49

Coming back to post #47, because the follow-up matters more than the original answer.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

30 likes 7d

KStephanopoulosTL3Regular22 Jul 2026 · edited#56

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

24 likes 6d

me.eriksenTL2 Moderator25 Jul 2026#68

d.fontaine, post #62: Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position. Go to post

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

28 likes in reply to #62 3d

f.petrovTL2 Moderator25 Jul 2026#72

k.salinas, post #67: I read post #65 twice before replying, because I had assumed the opposite. Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached. Go to post

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

22 likes in reply to #67 3d

y.ramosTL2 Moderator26 Jul 2026#76

m.perrin, post #63: Coming back to post #61, because the follow-up matters more than the original answer. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

29 likes in reply to #63 2d

Read the full topic (78 posts)

This topic was referenced in

Import rules for personal quantities, by jurisdiction, datedSourcing › Regulatory · 3 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Research-use-only labelling: what it means and what it does not — the long version Sourcing › Regulatory EMA research use only compounding Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…	+150	158	55k	14mo
Labelling requirements for research chemicals — the long version Sourcing › Regulatory MHRA research use only compounding personal import Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…		2	1.8k	2mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Sourcing › Regulatory MHRA research use only compounding Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. A logistics question, since the…	+50	56	780	8mo
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…	+72	78	23k	3mo
Labelling requirements for research chemicals Sourcing › Regulatory research use only MHRA FDA Under review Labelling requirements for research chemicals — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked for.…	+5	9	45k	4mo

Related topics — sharing the tags MHRA, personal import, research use only

Topic	Participants	Replies	Views	Activity
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…	+28	32	640	13mo
What changed in 2026, by region — does this still hold? Access › International personal import MHRA EMA telehealth Solved What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…	+20	25	50k	1d
Availability by country, dated, with primary sources — one year on Access › International personal import MHRA NHS Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…	+7	11	850	7mo
Revisiting: German, French and Dutch differences, compared Regional › European Union personal import formulary EMA cost per milligram Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…	+90	99	32k	9mo
Cross-border purchase rules within the EU Regional › European Union personal import formulary cost per milligram EMA On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…	+45	49	15k	8mo